SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polygon

Polygon is trending due to a notable surge in network usage and on-chain revenue, bolstered by initiatives like the Open Money Stack and consistent token burning. The community is expressing strong bullish sentiment, often citing its perceived undervaluation against rivals and actively discussing a potential return to its familiar MATIC ticker.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing high investor interest driven by its recent balance sheet strengthening through debt conversion and a notable multi-billion dollar task order win. While many in the community are speculating on an 'infinity short squeeze' due to reported high cost-to-borrow and low share availability, others are expressing concerns over recent share registration filings and potential dilution, leading to a highly volatile and polarized sentiment.

SuperCom Ltd. engages in the provision of traditional and digital identity solutions. It offers identification, tracking, and security products to government, private and public organization. It operates through the following divisions: e-Gov, Internet of Things (IoT), and Cyber Security. The e-Gov division provides solutions for traditional and biometrics enrollment, personalization, issuance and border control services. The IoT division products and services reliably identify, track, and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles, and monitored objects. The Cyber Security division is involved in the comprehensive solutions to protect the organization's sensitive data residing on servers, laptops, and detachable devices. The company was founded by Jack Hasan and Eli Rozen on July 4, 1988 and is headquartered in Tel Aviv, Israel.

SuperCom Ltd

SuperCom is trending as it secures significant new national electronic monitoring contracts, including a $7 million project in Germany and expansion into numerous U.S. states, effectively displacing incumbent technology providers. The community is actively engaged in discussions around these growing contracts and the company's strong profit margins, with many speculating on a potential game-changing federal deal, such as an ICE/ISAP contract, that could trigger a substantial revaluation given its remarkably low float.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is a top trending stock as investors actively debate the potential impact of proposed credit card interest rate caps, with many arguing such measures primarily affect card issuers rather than Visa's transaction-based revenue. The company also recently reported strong earnings, bolstered by continued global payment volume growth and strategic advancements in stablecoin settlements. Community discussions highlight Visa's resilient network effect and its expanding role in a rapidly evolving digital payments landscape.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a top trending ticker after a Bank of America downgrade and news of Amazon Pharmacy offering Novo Nordisk's oral GLP-1 directly, intensifying competition in the weight loss sector. Community sentiment is deeply divided, with many bears highlighting overvaluation and lack of a moat, while bulls see a compelling buying opportunity and anticipate a strong long-term rebound for the telehealth platform.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is generating significant buzz due to recent government contract awards for its BioThrax anthrax vaccine and expanded manufacturing capabilities for raxibacumab, solidifying its position in national biodefense. The community is actively discussing potential for increased Narcan contracts driven by policy changes, with many investors anticipating substantial future gains despite past volatility and ongoing debates around short interest.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is actively restructuring its debt profile through a significant asset sale and ongoing refinancing efforts, which are seen as critical steps toward improving its financial health. This strategic pivot aims to sharpen its focus on high-margin enterprise services, particularly leveraging its extensive fiber network to support growing AI infrastructure needs and deepen partnerships with major tech companies. The community is buzzing about Lumen's long-term potential in the AI-driven landscape, with many viewing it as an undervalued play despite recent market volatility and executive changes.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is gaining significant attention following robust Black Friday sales growth and its strategic move to launch KlarnaUSD, a dollar-backed stablecoin, signaling a strong push into crypto payments and Web3 banking. While recent earnings reflected a temporary profitability lag due to upfront credit loss provisions, the company's accelerating user growth, low delinquency rates, and ambitious vision as an AI-first neobank are driving strong community optimism. Investors are actively debating Klarna's undervalued position and its potential to disrupt traditional finance amidst evolving consumer spending habits and a competitive Buy Now, Pay Later market.

Global X Funds - Global X Silver Miners ETF

Silver is trending due to persistent supply deficits, surging industrial demand from sectors like solar and EVs, and geopolitical influences on physical metal flows, fundamentally shifting its market dynamics. Community discussion highlights the metal's resilience to short-term market fluctuations and rebalancing events, with many anticipating a significant catch-up rally for silver miners (SIL) given their perceived undervaluation relative to the rising spot price.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is a top trending stock following a significant multibillion-dollar fuel cell purchase agreement with American Electric Power, alongside a substantial microgrid deal with Quanta. The community is abuzz about how these contracts underscore BE's crucial role in providing immediate, on-site power solutions for the rapidly expanding AI data center infrastructure, driving discussions around its growth potential despite its historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

Equity

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen research firms that are covering the stock, MarketBeat reports. Three...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.7% - Should You Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 7.7% - Time to Sell...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6% - Still a Buy?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 6% - Here's Why...

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of...

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit MLTX Deadline: MLTX Investors with Losses in Excess of $100K...

MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX MLTX DEADLINE: Faruqi & Faruqi Reminds...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

MoonLake Immunotherapeutics

Traders are buzzing about an imminent buyout, with speculation centered around Merck making an offer in the $75-$95 range, possibly tied to the J.P. Morgan conference.

With a reported 13.73% of the float short and growing buying pressure, many anticipate a significant short squeeze pushing prices much higher.

Positive FDA feedback and clear Biologics License Application (BLA) pathway for sonelokimab are significantly derisking the asset, boosting investor confidence.

Recent Form 4 filings showing RSU grants and options for executives are sparking debate among traders on whether these signal strong insider conviction or are routine compensation.

Following recent gains, traders are eagerly anticipating further price surges, with many setting immediate targets of $20+ and long-term aspirations of $60 or higher.

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MLTX News

MLTXMoonLake Immunotherapeutics